A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis
NCT02546323
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
543
Enrollment
INDUSTRY
Sponsor class
Conditions
Atherosclerosis
Interventions
DRUG:
Rosuvastatin
DRUG:
Placebo
Sponsor
AstraZeneca